Allogene Therapeutics (ALLO) Change in Accured Expenses (2018 - 2026)

Allogene Therapeutics has disclosed Change in Accured Expenses across 9 years of filings, most recently posting -$5.1 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$5.1 million, up 2.34% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.4 million (down 201.64% YoY), and the FY2025 annual result was -$2.5 million, down 99.68% from the prior year.
• Change in Accured Expenses came in at -$5.1 million for Q1 2026 at Allogene Therapeutics, down from -$118000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $5.7 million in Q2 2022 to a low of -$12.7 million in Q3 2023.
• The 5-year median for Change in Accured Expenses is $286000.0 (2023), against an average of -$821000.0.
• Peak annual rise in Change in Accured Expenses reached 906.99% in 2024, while the deepest fall reached 1140.51% in 2024.
• Allogene Therapeutics' Change in Accured Expenses stood at $3.1 million in 2022, then tumbled by 90.88% to $286000.0 in 2023, then surged by 906.99% to $2.9 million in 2024, then slumped by 104.1% to -$118000.0 in 2025, then sank by 4222.88% to -$5.1 million in 2026.
• The last three Change in Accured Expenses figures came in at -$5.1 million (Q1 2026), -$118000.0 (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.